Veracyte, Inc.
NASDAQ:VCYTBiotechnology
+$1.83 today
- Market cap
- $2.06B
- Beta
- 1.98
- P/E (TTM)
- 48.0
- EPS (TTM)
- $1.11
Volume 2.45M
Average 1.05M
VCYT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Veracyte, Inc.NASDAQ: VCYT
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $29.44M rose 81.0% year over year, ahead of the +31.8% change in trailing-twelve-month research & development. Sequentially, it rose 8.7% from the prior quarter. Over 3 fiscal years it compounded at +20.4% a year.
Context
- Research & development amounted to 13.7% of revenue in FY2025, down 1.9 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +81.0% holds above the trailing-twelve-month pace of +31.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 70.81M USD
- Year-over-year change
- +2.2%
- 4-year CAGR
- +24.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 70.81M | +2.2% |
| FY2024 | 2024-12-31 | 69.29M | +20.9% |
| FY2023 | 2023-12-31 | 57.31M | +41.1% |
| FY2022 | 2022-12-31 | 40.6M | +36.1% |
| FY2021 | 2021-12-31 | 29.84M | — |
Research & Development vs competitors
How VCYT compares with its peers on the latest reported figures
- VCYT's LTM Jun 2026 research & development of $93.37M is the 3rd highest of the 10 companies compared; the peer median is $53.69M.
- Its year-over-year change of +31.8% is the 4th highest of 10, against a peer median of +9.5%.
- Research & development amounts to 16.6% of revenue for VCYT, versus a peer median of 15.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $386.67M | +7.6% | -0.9% | 30.2% | |
| LTM Mar 2026 | $106.4M | -7.7% | +7.7% | 12.8% | |
| LTM Jun 2026 | $93.37M | +31.8% | +20.4% | 16.6% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $83.32M | +64.3% | -5.8% | 18.3% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $59.21M | +38.6% | — | 14.9% |
| LTM Mar 2026 | $53.69M | +5.8% | +4.9% | 15.8% | |
| LTM Mar 2026 | $52.16M | +6.9% | -8.2% | 80.9% | |
| LTM Jun 2026 | $38.17M | +9.5% | +6.9% | 5.0% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $17.59M | +68.3% | +29.6% | 902.4% |
| LTM Mar 2026 | $12.42M | +19.5% | -2.9% | 12.9% | |
| Peer median (excluding VCYT) | $53.69M | +9.5% | +2.0% | 15.8% | |
Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 219.51M | 296.54M | 361.05M | 445.76M | 517.15M |
| Cost of Revenue | 74.4M | 101.58M | 112.9M | 147.62M | 157.1M |
| Gross Profit | 145.11M | 194.95M | 248.15M | 298.15M | 360.05M |
| Gross Margin | 66.1% | 65.7% | 68.7% | 66.9% | 69.6% |
| Research & Development | 29.84M | 40.6M | 57.31M | 69.29M | 70.81M |
| Selling, General & Admin | 181.19M | 174.08M | 184.23M | 206.04M | 210.95M |
| Operating Expenses | 227.02M | 236.04M | 333.94M | 282M | 285.9M |
| Depreciation & Amortization | 19.59M | 25.93M | 27.19M | 23.46M | 21.42M |
| EBITDA | (61.82M) | (10.3M) | (49.41M) | 49.21M | 89.62M |
| EBITDA Margin | -28.2% | -3.5% | -13.7% | 11.0% | 17.3% |
| Operating Income | (81.9M) | (41.08M) | (85.8M) | 16.14M | 74.15M |
| Operating Margin | -37.3% | -13.9% | -23.8% | 3.6% | 14.3% |
| Interest Income | 135K | 1.97M | 7.34M | 11.15M | 0 |
| Interest Expense | 241K | 198K | 15K | 2K | 0 |
| Other Income / Expenses | 254K | 4.65M | 9.18M | 9.6M | (5.95M) |
| Income Before Tax | (81.65M) | (36.43M) | (76.61M) | 25.74M | 68.2M |
| Pre-Tax Margin | -37.2% | -12.3% | -21.2% | 5.8% | 13.2% |
| Income Tax Expense | (6.09M) | 133K | (2.21M) | 1.61M | 1.85M |
| Net Income | (75.56M) | (36.56M) | (74.4M) | 24.14M | 66.35M |
| Net Margin | -34.4% | -12.3% | -20.6% | 5.4% | 12.8% |
| EPS (Basic) | (1.11) | (0.51) | (1.02) | 0.32 | 0.84 |
| EPS (Diluted) | (1.11) | (0.51) | (1.02) | 0.31 | 0.82 |
| Weighted Avg Shares | 67.89M | 71.55M | 72.64M | 76.48M | 78.58M |
| Weighted Avg Shares (Diluted) | 67.89M | 71.55M | 72.64M | 78.16M | 80.57M |
Veracyte, Inc.
NASDAQ:VCYT
Intrinsic Alpha fair value
Locked
Current Price
$25.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.